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Abstract
Background—People with HIV initiating combination antiretroviral therapy are at risk for
tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS). While this
syndrome has been well researched in adults, little is known about the incidence, case fatality,
underlying immunopathology and treatment approaches in children.
Methods—Major databases were searched for articles related to TB-IRIS in children. Data were
abstracted using standardized forms.
Results—Thirteen studies were identified: 6 retrospective and 2 prospective cohort studies, 1
cross-sectional study, 3 case reports and 1 case series. In total, 303 cases of TB-IRIS were
described, of which 270 were unmasking TB-IRIS, 12 paradoxical TB-IRIS and 21 were not
classifiable due to lack of key information. None of the cohort studies had investigation of TB-
IRIS as its primary aim. Nine studies were from Africa, 3 from Asia and 1 from Latin America.
Age at cART initiation (reported by 12 studies) ranged from 1 month to 16 years. Median time
from start of cART to IRIS diagnosis (reported by 8 studies) ranged from 8 days to 16 weeks. Few
deaths attributable to TB-IRIS were recorded. Treatment was only discussed in 2 case studies,
both of which reported children receiving corticosteroids. No studies evaluated risk factors for, or
immunopathogenesis of, pediatric TB-IRIS.
Conclusions—There is a paucity of information available on TB-IRIS in children. Future
research assessing incidence, risk factors, case fatality and optimal treatment or prevention
strategies of TB-IRIS is needed.
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Despite major advances in the prevention of mother-to-child transmission of HIV, 330,000
children were newly infected with HIV in 2011. Of the estimated 3.3 million children living
with HIV, the majority are in Africa and approximately 562,000 received combination
antiretroviral treatment (cART) in 2011.1-3
cART substantially reduces the occurrence of tuberculosis (TB) and mortality in children
living with HIV.4-6 The beneficial effects are mediated by suppression of HIV replication
and increased CD4 cell count.7 In some, initiation of cART is complicated by immune
reconstitution inflammatory syndrome (IRIS), whereby the individual experiences clinical
deterioration within the first 6 months of initiating cART despite exhibiting immune
reconstitution as evidenced by an increase in their CD4 counts and reduction in HIV-1 viral
load (VL).8 While the immunopathological processes underlying IRIS are not yet fully
understood, it is generally accepted that IRIS is a consequence of an exaggerated or
dysregulated immune response against a pathogen.9 In the case of “paradoxical” IRIS, this
pathogen is responsible for an infection that is diagnosed and treated; in “unmasking” IRIS,
the pathogen is the cause of a latent or subclinical infection. IRIS has been associated with a
wide array of pathogens, of which Mycobacterium tuberculosis, Cryptococcus and
cytomegalovirus are the most common.10-13
In adults initiating cART, a meta-analysis estimated that 15.7% (95% confidence interval:
9.7–24.5%) of patients worldwide develop paradoxical TB-IRIS.14 In addition, an estimated
5% develop unmasking TB-IRIS.15,16 The adult case-fatality rate of TB-IRIS is relatively
low, about 3.2%, with the highest case-fatality rate observed in TB-IRIS that involves the
central nervous system.14,17,18 Development of TB-IRIS in adults is known to be associated
with low CD4 cell counts, disseminated TB infection and early antiretroviral therapy (ART)
initiation after anti-TB treatment.8,16,17,19 Treatment of TB-IRIS in adults generally consists
of continuation of cART and continuation or initiation of appropriate anti-TB treatment,
administration of non-steroid, anti-inflammatory drugs or treatment with steroids in more
severe cases and interruption of cART in life-threatening cases.20
While many studies have investigated TB-IRIS in adults, there is a paucity of information on
TB-IRIS in children. We aimed to systematically review studies that have evaluated TB-
IRIS in children to define the incidence, case fatality, risk factors and treatment regimens for
pediatric TB-IRIS.
MATERIALS AND METHODS
We conducted a systematic literature review on pediatric TB-IRIS. We searched the
electronic databases MEDLINE and EMBASE from 1999 (when cART was introduced) to
May 2013 for published reports with the terms “TB-IRIS,” “HIV and IRIS,” “unmasking
TB,” “paradoxical TB” and “TB and antiretrovirals,” as well as all MeSH terms and
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abbreviations relating to these terms. No language restrictions were used. Included in the
review were epidemiological studies, case studies and case series, in children (0–17 years of
age) receiving cART for HIV infection. Articles presenting both adult and pediatric data
stratified by age were included. Similarly, articles reporting on multiple pathogen-specific
types of IRIS were included if results included TB-specific IRIS. Articles were excluded if
results did not distinguish between children and adults or between TB-IRIS and other types
of IRIS.
Abstracts identified in the original search were independently screened by 2 reviewers
(R.L.G. and A.V.R.) for inclusion and exclusion criteria. When abstracts did not include
sufficient information to determine whether the article met the inclusion criteria, the article
was reviewed in full. All selected articles were assessed to determine whether they met the
inclusion criteria for final review. References of all selected articles were reviewed to
identify potential additional eligible publications. Next, a structured data abstraction tool
was used to extract study characteristics, including study design, population, location, study
population demographics, baseline CD4 count or CD4 percent, baseline viral load, cART
regimen, TB-IRIS definition and diagnostic criteria used by the original study, type of TB-
IRIS and TB-IRIS incidence, treatment and outcomes.
RESULTS
The search yielded 385 articles, of which 320 were excluded based on abstract review (see
Figure, Supplemental Digital Content 1, http://links.lww.com/INF/B745). Of the 65 full
articles screened, 49 were excluded, mostly because the article did not include children, did
not stratify results by children versus adults or addressed TB in people receiving cART but
did not present data specifically on TB-IRIS. One additional publication was identified from
the references of the 16 selected articles. Upon detailed review, 3 of these 17 articles were
excluded, 1 because of insufficient information on timing of TB diagnosis in relation to
starting cART, resulting in the inability to classify TB on cART as TB-IRIS, 1 due to the
absence of information to reliably diagnose IRIS and 1 because of a lack of information on
TB-IRIS in children.21-23 Finally, 1 publication was excluded as it was a review of case
studies already included in the articles selected for systematic review.24,25 The remaining 13
articles included 6 retrospective cohort studies, 2 prospective cohort studies, 1 cross-
sectional study, 3 case studies (1 unmasking TB-IRIS and 2 paradoxical TB-IRIS) and 1
case series reporting on 7 cases of paradoxical and 4 cases of unmasking TB-IRIS (Table
1).25-37 In total, 303 cases of TB-IRIS were reported. Most (270, 89.1%) were cases of
unmasking TB-IRIS and only 12 (4.0%) were cases of paradoxical TB-IRIS. The remaining
21 cases were not classified as paradoxical or unmasking in the original publication. Most
studies did not report the extent to which TB was excluded at time of cART initiation, the
age at TB-IRIS diagnosis or the median time from cART initiation to TB-IRIS diagnosis. Of
the 12 publications reporting age at TB-IRIS diagnosis, the range was 1 month to 16 years.
This needs to be interpreted in light of eligibility criteria for the individual studies as several
studies restricted age of study participants to, for example, children <24 months or <13
years.27,28 Among the 8 publications that reported median time from cART initiation to TB-
IRIS, the range was broad, from a median of 8 days to 16 weeks.27,33
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Only 2 articles reported on potential risk factors for TB-IRIS. Factors assessed included HIV
clinical stage, baseline CD4 count or HIV viral load at cART initiation. In Shah,32 3 of the 7
children diagnosed with IRIS were classified as World Health Organization clinical stage 4,
compared with 53% of the 30 children who remained free of IRIS during follow up.
Unfortunately, results were not stratified by type of IRIS in this study, which included
different types of IRIS and only 2 children with a specific diagnosis of TB-IRIS.32 Walters
et al28 did focus specifically on the clinical presentation and outcome of TB in HIV-infected
children on cART. They recorded 137 TB episodes among 290 children; 116 episodes
before and 21 after cART initiation. Of these, 10 were considered probable TB-IRIS cases.
Potential risk factors, such as level of immunodeficiency, World Health Organization
clinical stage, nutritional status and history of TB, were compared and found to be
significantly different, for children diagnosed with TB in the first 6 months of cART (n =
14) and those diagnosed with TB after 6 months of cART (n = 7). However, these risk
factors were not compared between children with and without probable TB-IRIS.28
None of the cohort or cross-sectional studies reported on specific treatment for TB-IRIS.
Two case studies recorded some treatment information. Narendran et al36 reported
successful TB-IRIS treatment in a case of paradoxical lymph nodal TB with prednisolone
and continued anti-TB treatment. The child reported on by Rabie et al37 had complications
after initial anti-TB therapy and required a more complicated treatment course, consisting of
oral and intravenous steroids, an intercostal drain and finally subcutaneous octreotide.
Treatment appeared successful, but the child remained hospitalized for 113 days.
Few deaths were reported in children with TB-IRIS. In a study of IRIS in South African
children initiating cART, 1 of 12 children diagnosed with TB-IRIS died. This child was 8
months of age and on cART for 13 days at the time of IRIS diagnosis, but also had a
diagnosis of disseminated Bacillus Calmette-Guérin (BCG) disease.27 Walters et al28
reported 16 deaths, 15 (94%) of which occurred in children diagnosed with TB before cART
initiation. According to the authors, 4 deaths may have been partly attributable to IRIS, but
it was impossible to establish with certainty whether IRIS was a contributory cause of death
in these children. Two cases, 1 with intestinal perforation and 1 with acute upper airway
obstruction, showed good immune recovery at death but occurred >5 months after cART
initiation. Two other deaths also demonstrated excellent immune recovery on cART, but
both had multidrug-resistant TB.28
DISCUSSION
In contrast to adult TB-IRIS, very little information is available on TB-IRIS in children.
Even though our analysis was based on a comprehensive search of published reports, only
13 publications could be included, of which only 3 were prospective cohort studies. None of
the cohort studies identified were designed to study TB-IRIS in children. Rather, they
included numerous types of IRIS or focused on any TB occurring in children on cART and
were thus not limited to TB-IRIS. Consequently, the available literature did not allow us to
estimate the overall TB-IRIS incidence in children initiating cART, nor the incidence of
unmasking or paradoxical TB-IRIS in children. In addition, the dearth of information
precluded our ability to gain any insight into risk factors for developing TB-IRIS, the case-
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fatality rate of pediatric TB-IRIS or best practices for treatment of children initiating cART
who develop TB-IRIS. Because of the paucity of data available, we were also not able to
conduct a meta-analysis to estimate incidence, case-fatality rate or TB-IRIS risk factors.
While it is possible that pediatric TB-IRIS shares many characteristics in incidence, risk
factors and immunopathogenesis of TB-IRIS in adults, the developing pediatric immune
system is likely to result in important differences in host immune response and
pathophysiology of TB between adults and children. Independent of coinfection with
opportunistic infections, following HIV infection, children exhibit a rapid progression to
disease with high early morbidity and mortality compared with adults.38 Mechanisms likely
involve a complex interplay between severely reduced HIV-specific CD4 and CD8 T cell
responses and anti-HIV humoral immune responses.39-41 For TB, both innate and adaptive
immune cells form the defense against mycobacteria, but both systems can be impaired in
children.42 For example, neutrophils play an important role in the innate immune response,
but infant neutrophils have decreased granulocyte functions and decreased responsiveness to
cytokine stimulations.43 Compared with adults, infant macrophages infected by M.
tuberculosis have poorer phagocytosis.44 Neonates also have fewer circulating dendritic
cells with lower capacity to synthesize IL-12 and an impaired major histocompatibility
complex II pathway, which is important for stimulation of CD8 T-cells.29,45,46 Similar to
adults, CD4 and CD8 T-cell-mediated immunity play a key adaptive role in host defense
against mycobacteria, but this defense is impaired in HIV-infected children.45,46
To better understand the characteristics specific to pediatric TB-IRIS, additional research is
needed. Prospective studies should be designed to determine the incidence and case-fatality
rate of TB-IRIS in general, and paradoxical and unmasking TB-IRIS in a specific cohort of
children initiating cART. Prospective studies should also evaluate whether the case
definitions that have been developed for TB-IRIS in resource-limited settings are valid for
the diagnosis of TB-IRIS in children in similar settings.47 To ensure that health care workers
can identify those children at highest risk of developing TB-IRIS, prospective studies should
elucidate the strength of association between risk factors such as time since cART initiation,
baseline viral load and baseline CD4 percentage and nutritional status and the development
of TB-IRIS in children. Finally, further research is needed to understand the
immunopathogenesis of TB-IRIS in children, to investigate potential overlap with BCG-
IRIS and to identify the optimal treatment or prevention strategies.48 These areas of research
are particularly important given the increasing numbers of children initiating cART,
especially young children, and the need for pediatric-specific cART and TB treatment
regimens.
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